Cat. No.: HY-17505

Candesartan Cilexetil

(Synonyms: TCV-116)

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure.

For research use only. We do not sell to patients.

Purity: 99.66%
CAS No.: 145040-37-5
Formula: C₃₃H₃₄N₆O₆
Molecular Weight:610.66

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Candesartan Cilexetil Chemical Structure

CAS No.: 145040-37-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All Angiotensin Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	IC₅₀	>100 μM Compound: 1; CDC, MT04D0301	Cytotoxicity against human 16HBE cells after 48 hrs by CCK-8 assay Cytotoxicity against human 16HBE cells after 48 hrs by CCK-8 assay	[PMID: 31732254]
A-431	IC₅₀	2.6 μM Compound: Candesartan cilexetil	Inhibition of IDO in human A431 cells assessed as kynurenine production after 24 hrs Inhibition of IDO in human A431 cells assessed as kynurenine production after 24 hrs	10.1039/C2MD00278G
A549	IC₅₀	63.93 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human A549 cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
A549	IC₅₀	65.92 μM Compound: 1; CDC	Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay	[PMID: 33129593]
BEAS-2B	IC₅₀	79.76 μM Compound: 1; CDC	Cytotoxicity against human BEAS-2B cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human BEAS-2B cells incubated for 48 hrs by CCK-8 assay	[PMID: 33129593]
BEAS-2B	IC₅₀	89.94 μM Compound: 1; CDC, MT04D0301	Cytotoxicity against human BEAS2B cells after 48 hrs by CCK-8 assay Cytotoxicity against human BEAS2B cells after 48 hrs by CCK-8 assay	[PMID: 31732254]
EKVX	IC₅₀	>100 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human EKVX cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human EKVX cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
HepG2	IC₅₀	>100 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human HepG2 cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
Huh-7	IC₅₀	>100 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human HuH7 cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human HuH7 cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
MCF7	IC₅₀	>100 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human MCF7 cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
MGC-803	IC₅₀	57.14 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human MGC803 cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human MGC803 cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
MKN-45	IC₅₀	68.87 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human MKN45 cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human MKN45 cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
NCI-H1299	IC₅₀	45.02 μM Compound: 1; CDC	Antiproliferative activity against human H1299 cells incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human H1299 cells incubated for 48 hrs by CCK-8 assay	[PMID: 33129593]
NCI-H1299	IC₅₀	45.11 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human H1299 cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human H1299 cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
PLC	IC₅₀	60.21 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human PLC cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human PLC cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]
T47D	IC₅₀	64.35 μM Compound: 1; CDC, MT04D0301	Antiproliferative activity against human T47D cells measured after 48 hrs by CCK8 assay Antiproliferative activity against human T47D cells measured after 48 hrs by CCK8 assay	[PMID: 31732254]

In Vitro

Candesartan Cilexetil (0.1-10 μM, 24 h) exhibits antiviral effects against ZIKV in HUVEC cells, HEK293T cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HUVEC cells, HEK293T cells
Concentration:

0.1 μM, 1 μM, 5 μM, 10 μM
Incubation Time:

24 h
Result:

Showed a dose-dependent antiviral effect in ZIKV-infected HUVEC and HEK293T cells.

In Vivo

Candesartan Cilexetil (5 mg/kg, Oral gavage, once a day for 7 weeks) ameliorates myocardial remodeling and heart failure in Dahl salt-sensitive (DS) rats fed a high-salt diet^[2].
Candesartan Cilexetil (1-10 mg/kg, Oral, once a day for 15 days) has an effect of skin wound healing in rats^[3].
Candesartan Cilexetil (1-10 mg/kg, Administered through a stomach tube, once a day for 4-12 weeks) inhibits the increase in blood pressure in spontaneously hypertensive rats^[5].
Candesartan Cilexetil (10 mg/kg, Oral, supplemented in drinking water, for 2-23 days) inhibits the synthesis of TGF-b1 and ameliorates the pulmonary fibrosis in bleomycin (HY-108345) induced pulmonary fibrosis model rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Dahl salt-sensitive hypertensive rats^[2]
Dosage:

5 mg/kg
Administration:

Oral gavage (p.o.)
Result:

Increased body weight and decreased left ventricular end-diastolic diameter.
Decreased the level of iNOS mRNA and ADM mRNA in the left ventricle (LV).
Increased the eNOS protein mass in the LV and decreased the immunoreactive ADM contents of LV.
Enhanced immunoreactivity for eNOS.
Significantly decreased the degree of perivascular fibrosis.

Animal Model:

Skin wound model rat ^[3]
Dosage:

1 mg/kg, 10 mg/kg
Administration:

Oral
Result:

Showed 100% re-epithelization of the wound at 1 mg/kg.
Significantly suppressed angiogenesis at 10 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 145040-37-5
Appearance Solid
Molecular Weight 610.66
Formula C₃₃H₃₄N₆O₆
Color White to off-white
SMILES

O=C(C1=C2C(N=C(OCC)N2CC3=CC=C(C4=CC=CC=C4C5=NNN=N5)C=C3)=CC=C1)OC(OC(OC6CCCCC6)=O)C
Synonyms

TCV-116
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All

Sort by:

Journal Impact Factor

Biomed Pharmacother

A low-salt diet with candesartan administration is associated with acute kidney injury in nephritis by increasing nitric oxide. [Abstract]

2023 May:161:114484. PMID: 36921530
Cell Death Discov

Single cell RNA sequencing reveals the role of local renin-angiotensin system in regulating ovarian physiological cycle and promoting PCOS. [Abstract]

2025 May 27;11(1):255. PMID: 40425574
Int J Mol Sci

Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals. [Abstract]

2026 Mar 11;27(6):2587. PMID: 41898448
EXCLI J

Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses. [Abstract]

2026 Jan 16:25:204-221. PMID: 41768859
Research Square Preprint

2020 Aug.

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (81.88 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6376 mL

8.1879 mL

16.3757 mL

5 mM

0.3275 mL

1.6376 mL

3.2751 mL

10 mM

0.1638 mL

0.8188 mL

1.6376 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Loe M W C, et al. Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection [J]. Antiviral Research, 2019, 172: 104637. [Content Brief]

[2]. Kobayashi N, et al. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats [J]. Atherosclerosis, 2001, 156(2): 255-265. [Content Brief]

[3]. Takeda H, et al. Effects of angiotensin II receptor signaling during skin wound healing [J]. The American journal of pathology, 2004, 165(5): 1653-1662. [Content Brief]

[4]. McClellan K J, et al. Candesartan cilexetil: a review of its use in essential hypertension [J]. Drugs, 1998, 56: 847-869. [Content Brief]

[5]. Kojima M, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro [J]. Circulation, 1994, 89(5): 2204-2211. [Content Brief]

[6]. Otsuka M, et al. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist [J]. Thorax, 2004, 59(1): 31-38. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6376 mL	8.1879 mL	16.3757 mL	40.9393 mL
	5 mM	0.3275 mL	1.6376 mL	3.2751 mL	8.1879 mL
	10 mM	0.1638 mL	0.8188 mL	1.6376 mL	4.0939 mL
	15 mM	0.1092 mL	0.5459 mL	1.0917 mL	2.7293 mL
	20 mM	0.0819 mL	0.4094 mL	0.8188 mL	2.0470 mL
	25 mM	0.0655 mL	0.3275 mL	0.6550 mL	1.6376 mL
	30 mM	0.0546 mL	0.2729 mL	0.5459 mL	1.3646 mL
	40 mM	0.0409 mL	0.2047 mL	0.4094 mL	1.0235 mL
	50 mM	0.0328 mL	0.1638 mL	0.3275 mL	0.8188 mL
	60 mM	0.0273 mL	0.1365 mL	0.2729 mL	0.6823 mL
	80 mM	0.0205 mL	0.1023 mL	0.2047 mL	0.5117 mL

Keywords

Candesartan Cilexetil

5 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Candesartan Cilexetil

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Candesartan Cilexetil

All Angiotensin Receptor Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Candesartan Cilexetil Related Classifications

Cat. No.: HY-17505